🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Tiffany Sia MD Ginger J. Gardner Dmitriy Zamarin MD PhD 👏👏👏

Love ovarian cancer? Hate ovarian cancer? You’re not alone! Submit your abstracts to the Biennial Rivkin-AACR Ovarian Cancer Research symposium! This will be a fantastic meeting with the latest and greatest in ovarian cancer research. myemail-api.constantcontact.com/Abstracts-due-…

My colleagues and I have prepared the best lineup for speakers in Translational Oncology NRG Oncology National Cancer Institute @NCItreatment Sidney Kimmel Comprehensive Cancer Center Jefferson Health Dmitriy Zamarin MD PhD All are welcome!

Ovarian cancer is one of several gynecologic malignancies, impacting about 300,000 women each year. During #OvarianCancerAwarenessMonth, learn how CRI-funded researchers, including CRI Lloyd J. Old STAR Stacy Malaker Yale University Yale Chemistry, are making an impact: bit.ly/4gmGTeV

Excited and honored to co-lead our newly-established Center of Excellence for Gynecologic Cancer Mount Sinai Health System with the amazing Stephanie Blank.

Thank you Cancer Research Institute for the opportunity to participate in this patient education series! #OvarianCancerAwarenessMonth

Ovarian Cancer, watch out: the biennial Rivkin Center-AACR Ovarian Cancer Symposium is about to start! Honored to be on this year’s organizing committee and look forward to the amazing scientific and education sessions. ⁦@RivkinCenter⁩ ⁦AACR⁩ rivkin.org/event/ovarian-…

What an inspiring 4 days at the 15th HHMT Intl Forum on Ovarian Cancer!Sharing our research and collaborating to overcome ovarian cancer Kunle Odunsi, MD Ernst Lengyel Ronny Drapkin 🎗 Dmitriy Zamarin MD PhD Anniina Färkkilä Stephanie Lheureux @rugangzhang @OCRAhope@OvarianCancerUK #forourpatients

Special thanks to our amazing collaborators Anna Vähärautio and Dmitriy Zamarin MD PhD for their invaluable contributions, and to the DoD, NIH, and The Mark Foundation for Cancer Research for supporting this research.

New #JITC article: Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors bit.ly/492Miok Diwakar Davar, M.D. Fernanda Arnaldez Sandip Patel MD FASCO Dmitriy Zamarin MD PhD

Check out our new story! Mechanisms of innate and adaptive immune activation in cancer cells deficient in SMARCA4. Thank you to the multiple collaborators that made it possible. Nicolas Vabret Benjamin D. Greenbaum Mithat Gönen Kate Chiappinelli @chiappinellilab.bsky.social science.org/doi/full/10.11…

This paper is the result of an incredibly fun collaboration with Sandro Santagata and Peter Sorger. Led by the fantastic Tanjina Kader 🎗️ with Jia-Ren Lin, we provide a pre-cancer atlas of Fallopian tube precursors to HGSOC. Don't miss our cbioportal entry of all the data!

The ASCI’s 2025 Active and International elected members beta.the-asci.org/news/asci-news… Congratulations to new members from Icahn School of Medicine at Mount Sinai - Joshua Brody, MD Dmitriy Zamarin MD PhD Keith Sigel

SMARCA4 inhibition enhances NK-mediated killing of senescent cells and can be combined with cisplatin to treat ovarian cancer science.org/doi/10.1126/sc… science.org/doi/10.1126/sc… Science Advances Virinder Reen Dmitriy Zamarin MD PhD

Our ⁦NRG Oncology⁩ GY017 trial of neoadjuvant or concurrent atezolizumab+CRT in locally advanced cervical cancer is out! Neoadjuvant IO led to favorable outcomes and persistence of tumor-resident TCRs in blood. Implications for optimal IO and RT sequence. nature.com/articles/s4146…

Join us on Feb. 28 for the Society for Immunotherapy of Cancer #LearnACI live virtual Women’s Malignancies program featuring in-depth education on all aspects of clinical implementation of IO for women’s malignancies. Learn more and register: sitcancer.org/education/aci/…